Hoechst Marion Roussel Priftin
Executive Summary
Rifapentine NDA (50-752) for treatment of pulmonary tuberculosis will be reviewed by FDA's Antiviral Drugs Advisory Committee May 5. The NDA was submitted Feb. 20 and will receive a priority review. The meeting begins at 8 a.m., with a closed session to be held from 10:30 a.m. to 12 p.m., at the Hilton in Gaithersburg, Md...